✦ LIBER ✦

End points for cardiovascular drug trials in pediatric patients

✍ Scribed by Alan R. Sinaiko; Ronald M. Lauer; Stephen P. Sanders

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Surrogate end points in cardiovascular d

✍ Thomas R. Fleming 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 434 KB

Surrogate End Points in Secondary Analys

✍ Kevin A. Buhr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Are Surrogate End Points in Drug-Eluting

✍ Pierfrancesco Agostoni; Giuseppe G.L. Biondi-Zoccai 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Surrogates, substudies, and real clinica

✍ Dean J. Kereiakes; Richard E. Kuntz; Laura Mauri; Mitchell W. Krucoff 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Evolving end points for clinical trials

✍ Sharlene Gill; Daniel J. Sargent 📂 Article 📅 2009 🏛 Current Science Inc. 🌐 English ⚖ 251 KB

End Points for Clinical Trials in Acute

✍ Larry A. Allen; Adrian F. Hernandez; Christopher M. O'Connor; G. Michael Felker 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 473 KB